Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial

NCT03359018 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03359018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03359018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2018
Completion date
January 30, 2020
Enrollment
43 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clinical benefit rate, overall survival, progression-free survival, toxicity